Allianz SE boosted its stake in shares of Medtronic PLC (NYSE:MDT – Free Report) by 9.9% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 86,294 shares of the medical technology company’s stock after buying an additional 7,796 shares during the period. Allianz SE’s holdings in Medtronic were worth $7,446,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds also recently added to or reduced their stakes in MDT. Meramec Financial Planners LLC raised its stake in shares of Medtronic by 4.9% in the third quarter. Meramec Financial Planners LLC now owns 2,171 shares of the medical technology company’s stock worth $187,000 after purchasing an additional 101 shares during the last quarter. Genesis Private Wealth LLC raised its holdings in shares of Medtronic by 2.0% during the third quarter. Genesis Private Wealth LLC now owns 5,170 shares of the medical technology company’s stock valued at $446,000 after purchasing an additional 103 shares during the last quarter. LightSquare Wealth Management LLC raised its holdings in shares of Medtronic by 3.6% during the third quarter. LightSquare Wealth Management LLC now owns 2,932 shares of the medical technology company’s stock valued at $253,000 after purchasing an additional 103 shares during the last quarter. Kennebec Savings Bank lifted its position in Medtronic by 1.2% during the third quarter. Kennebec Savings Bank now owns 9,201 shares of the medical technology company’s stock valued at $794,000 after purchasing an additional 110 shares during the period. Finally, Petredis Investment Advisors LLC lifted its position in Medtronic by 0.4% during the third quarter. Petredis Investment Advisors LLC now owns 26,369 shares of the medical technology company’s stock valued at $2,275,000 after purchasing an additional 114 shares during the period. Institutional investors own 82.06% of the company’s stock.
Wall Street Analyst Weigh In
A number of analysts recently commented on MDT shares. Piper Sandler upgraded Medtronic from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $85.00 to $120.00 in a research report on Tuesday. Wells Fargo & Company upped their price target on shares of Medtronic from $102.00 to $104.00 and gave the company an “overweight” rating in a research report on Wednesday, September 2nd. BTIG Research increased their price objective on shares of Medtronic from $99.00 to $109.00 and gave the stock a “buy” rating in a research note on Thursday. Robert W. Baird boosted their target price on shares of Medtronic from $91.00 to $100.00 and gave the company a “neutral” rating in a research report on Wednesday, September 2nd. Finally, Wall Street Zen downgraded shares of Medtronic from a “buy” rating to a “hold” rating in a research report on Monday, November 16th. Eighteen analysts have rated the stock with a Buy rating, eight have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $104.17.
Medtronic Trading Down 0.7%
Shares of MDT stock opened at $99.88 on Friday. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.07, a quick ratio of 1.54 and a debt-to-equity ratio of 0.50. The stock’s 50-day moving average price is $94.62 and its 200-day moving average price is $88.45. The stock has a market capitalization of $127.75 billion, a price-to-earnings ratio of 24.60, a price-to-earnings-growth ratio of 2.34 and a beta of 0.56.
Medtronic (NYSE:MDT – Get Free Report) last issued its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 EPS for the quarter, topping analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analysts’ expectations of $9.55 billion. Medtronic had a net margin of 13.93% and a return on equity of 14.78%. The business’s revenue was up 13.7% on a year-over-year basis. During the same period last year, the company posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Equities research analysts predict that Medtronic PLC will post 5.98 EPS for the current fiscal year.
Insider Buying and Selling at Medtronic
In other Medtronic news, EVP Michael Marinaro sold 10,420 shares of the company’s stock in a transaction on Thursday, October 15th. The stock was sold at an average price of $96.00, for a total value of $1,000,320.00. Following the completion of the sale, the executive vice president directly owned 105,916 shares in the company, valued at approximately $10,167,936. This represents a 8.96% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Harry Kiil sold 1,483 shares of the company’s stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $93.65, for a total value of $138,882.95. Following the completion of the sale, the executive vice president owned 42,186 shares of the company’s stock, valued at $3,950,718.90. This represents a 3.40% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 61,903 shares of company stock valued at $5,889,203 in the last ninety days. Corporate insiders own 0.27% of the company’s stock.
Medtronic Company Profile
Medtronic plc is a medical technology company that develops and manufactures devices and therapies for a range of health conditions. Its products include pacemakers and defibrillators, heart valves, surgical technologies, neurostimulation devices, and insulin pumps and other diabetes-management products. The company was founded in Minneapolis in 1949 by Earl Bakken and Palmer Hermundslie as a medical equipment repair business. It has since grown into a global company serving patients and health care providers in more than 150 countries.
See Also
- Five stocks we like better than Medtronic
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.
